Etanercept treatment for children and adolescents with plaque psoriasis

The New England Journal of Medicine
Amy S PallerEtanercept Pediatric Psoriasis Study Group

Abstract

Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis. In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body weight (to a maximum of 50 mg), followed by 24 weeks of once-weekly open-label etanercept. At week 36, 138 patients underwent a second randomization to placebo or etanercept to investigate the effects of withdrawal and retreatment. The primary end point was 75% or greater improvement from baseline in the psoriasis area-and-severity index (PASI 75) at week 12. Secondary end points included PASI 50, PASI 90, physician's global assessment of clear or almost clear of disease, and safety assessments. At week 12, 57% of patients receiving etanercept achieved PASI 75, as compared with 11% of those receiving placebo (P<0.001). A significantly higher proportion of patients in the etanercept group than in the placebo group had PASI 50 (75% vs. 23%), PASI 90 (27% vs. 7...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Jun 1, 1995·The British Journal of Dermatology·M S Lewis-Jones, A Y Finlay
Jun 1, 1995·Journal of the American Academy of Dermatology·T Henseler, E Christophers
Mar 1, 1993·International Journal of Dermatology·M A GuptaC N Ellis
Sep 17, 1998·Journal of the American Academy of Dermatology·M LebwohlG Weinstein
Jul 8, 2000·Pediatric Dermatology·S P Raychaudhuri, J Gross
Jul 5, 2001·Pediatric Dermatology·A MorrisK Williams
Mar 28, 2002·Clinical Chemistry and Laboratory Medicine : CCLM·Bekir Sami UyanikKübra Durkan
Aug 2, 2003·Journal of the American Academy of Dermatology·Alexandra R Brecher, Seth J Orlow
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 17, 2003·Archives of Dermatology·Alice B GottliebRalph Zitnik
Sep 24, 2004·Dermatologic Therapy·Debra Lewkowicz, Alice B Gottlieb
Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Dec 21, 2005·Archives of Dermatology·Mark D HerronGerald G Krueger
Dec 21, 2005·Archives of Dermatology·Joseph W McGowanSteven R Feldman
Feb 21, 2006·Journal of the American Academy of Dermatology·Alice B GottliebAngelika Jahreis
May 30, 2006·Arthritis and Rheumatism·Daniel J LovellUNKNOWN Pediatric Rheumatology Collaborative Study Group
Sep 16, 2006·Current Rheumatology Reports·Lotus MallbrisMona Ståhle
Sep 26, 2006·British Journal of Clinical Pharmacology·Ivan NestorovChristopher Banfield
Oct 6, 2006·Archives of Dermatological Research·Dorothea M SommerMichael Weichenthal
Oct 13, 2006·JAMA : the Journal of the American Medical Association·Joel M GelfandAndrea B Troxel

❮ Previous
Next ❯

Citations

Feb 27, 2009·Medizinische Klinik·Zhengguang ZhangWilhelm Kirch
Feb 3, 2009·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·G Wozel
Feb 4, 2009·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·S Benoit, H Hamm
Mar 3, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·M Sticherling
Mar 1, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·S Gerdes, U Mrowietz
May 11, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·F C BeikertM A Radtke
Dec 4, 2012·Dermatology and Therapy·Bruce E StroberMelodie Young
May 17, 2013·American Journal of Clinical Dermatology·Kara N Shah
Jun 30, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Jul 16, 2008·Current Opinion in Pediatrics·Leah Belazarian
Apr 21, 2010·Pediatric Dermatology·Sarah Toyomi de OliveiraRicardo Romiti
Apr 21, 2011·Pediatric Dermatology·Antonio Chaves AlvarezAntonio Zambrano
Mar 5, 2011·Pediatric Dermatology·Uxua FloristanRaul De Lucas
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Thao U Nguyen, John Koo
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jennifer D BahnerNeil J Korman
Jan 1, 2010·Clinical, Cosmetic and Investigational Dermatology·Philip M Laws, Helen S Young
Jul 1, 2010·American Journal of Clinical Dermatology·Srdjan ProdanovichFrancisco Kerdel
Jul 1, 2010·American Journal of Clinical Dermatology·Susan BardLawrence A Schachner
Sep 4, 2012·Drugs·Philip M Laws, Helen S Young
Jan 1, 2009·F1000 Medicine Reports·John Yost, Johann E Gudjonsson
Jul 8, 2010·Indian Journal of Dermatology·Raja K SivamaniEmanual Maverakis
Jul 27, 2010·Indian Journal of Dermatology, Venereology and Leprology·Sunil Dogra, Inderjeet Kaur
Nov 28, 2013·American Journal of Clinical Dermatology·Ashley L SembleSteven R Feldman
Jan 10, 2012·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·A DibiA Bentahila
Jun 18, 2014·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·E MahéM-L Sigal
Sep 23, 2014·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K Tenbrock
Apr 5, 2014·Archives of Disease in Childhood·Kate Khorsand, Robert Sidbury
Dec 7, 2014·Zeitschrift für Rheumatologie·H-I Huppertz, H W Lehmann
Jul 21, 2011·Indian Journal of Dermatology·Sandipan DharRajib Malakar
Nov 17, 2015·The Journal of Dermatological Treatment·V Di LerniaP Gisondi
Feb 4, 2016·The Journal of Dermatological Treatment·Tian Hao ZhuTina Bhutani
Aug 13, 2008·Expert Opinion on Therapeutic Targets·Francesca FantuzziGiampiero Girolomoni
Jan 1, 2014·Expert Review of Clinical Immunology·Maeve LynchRichard B Warren
Oct 29, 2013·Expert Opinion on Biological Therapy·Bobbak MansouriAlan Menter
May 29, 2012·Expert Opinion on Emerging Drugs·Vinod MalikJerry R Mendell
Sep 25, 2012·Expert Opinion on Drug Safety·Aleksandra Batycka-BaranJoerg C Prinz
Oct 17, 2008·Expert Opinion on Investigational Drugs·Katharine A WhartenbyPeter A Calabresi
Feb 13, 2016·Pediatric Dermatology·Daniel M KlufasBruce E Strober
Sep 23, 2010·Scandinavian Journal of Rheumatology·J C F van LuijnH G M Leufkens
May 8, 2010·Expert Opinion on Biological Therapy·Elizabeth E Uhlenhake, Steven R Feldman
May 18, 2013·Journal of the American Academy of Dermatology·Howard B PrideRobert Silverman
Apr 6, 2013·Dermatologic Clinics·Ann L Marqueling, Kelly M Cordoro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.